Haemonetics (NYSE:HAE) Updates FY 2026 Earnings Guidance

Haemonetics (NYSE:HAE) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.900-5.000 for the period, compared to the consensus estimate of 4.920. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.3 billion.

Wall Street Analyst Weigh In

Several research firms have commented on HAE. CJS Securities raised Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. increased their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Robert W. Baird set a $81.00 target price on shares of Haemonetics in a report on Friday. Finally, Mizuho dropped their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Trading Down 8.7%

Shares of HAE stock opened at $59.35 on Friday. The stock has a market cap of $2.78 billion, a P/E ratio of 16.35, a price-to-earnings-growth ratio of 1.35 and a beta of 0.28. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a current ratio of 1.75, a quick ratio of 1.03 and a debt-to-equity ratio of 1.01. The stock has a 50 day simple moving average of $76.84 and a 200 day simple moving average of $65.17.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. During the same period last year, the firm posted $1.19 earnings per share. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts predict that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q3 results beat consensus: HAE reported $1.31 EPS vs. $1.27 expected and revenue of $338.97M vs. ~$331.9M, with margins improving—evidence of profitable execution. Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company raised FY‑2026 outlook and signaled strong organic growth (management highlighted plasma and blood‑management strength and an 8%–10% organic growth outlook), which supports longer‑term revenue momentum. Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
• Positive Sentiment: Analyst support remains: BTIG reaffirmed a “buy” and a $88 price target, indicating continued analyst conviction above current levels. Benzinga coverage of BTIG rating
• Neutral Sentiment: Investor materials and transparency: the company posted its press release, slide deck and earnings‑call transcript for review—useful for digging into segment trends and guidance detail. PR Newswire: Q3 financial results available
• Neutral Sentiment: Zacks highlights HAE as a top‑ranked growth stock by style scores—an informational signal for growth‑oriented investors but not an immediate price catalyst. Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Revenue weakness and mixed investor reaction: revenue fell ~2.7% YoY despite the beat, and the market reacted negatively (shares slipped after the report)—suggesting investors wanted stronger top‑line improvement or more aggressive guidance. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. CIBC Private Wealth Group LLC increased its stake in Haemonetics by 69.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 448 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Haemonetics during the 3rd quarter valued at approximately $251,000. Danske Bank A S bought a new position in shares of Haemonetics in the third quarter worth $665,000. Caitong International Asset Management Co. Ltd grew its holdings in Haemonetics by 20,925.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 837 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its stake in Haemonetics by 3.7% during the third quarter. CANADA LIFE ASSURANCE Co now owns 35,438 shares of the medical instruments supplier’s stock valued at $1,706,000 after acquiring an additional 1,266 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.